Bristol-Myers Squibb (NYSE:BMY) Shares Purchased by Catalytic Wealth RIA LLC

Catalytic Wealth RIA LLC boosted its stake in Bristol-Myers Squibb (NYSE:BMY) by 33.1% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 9,086 shares of the biopharmaceutical company’s stock after purchasing an additional 2,258 shares during the period. Catalytic Wealth RIA LLC’s holdings in Bristol-Myers Squibb were worth $493,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of BMY. BKM Wealth Management LLC purchased a new stake in shares of Bristol-Myers Squibb during the fourth quarter worth $101,000. OneAscent Financial Services LLC purchased a new position in Bristol-Myers Squibb in the fourth quarter valued at $512,000. Brookstone Capital Management increased its holdings in Bristol-Myers Squibb by 15.2% in the fourth quarter. Brookstone Capital Management now owns 110,019 shares of the biopharmaceutical company’s stock valued at $5,645,000 after buying an additional 14,516 shares during the last quarter. Advisor Resource Council purchased a new position in Bristol-Myers Squibb in the fourth quarter valued at $626,000. Finally, Cedar Brook Financial Partners LLC increased its holdings in Bristol-Myers Squibb by 8.6% in the fourth quarter. Cedar Brook Financial Partners LLC now owns 10,917 shares of the biopharmaceutical company’s stock valued at $548,000 after buying an additional 869 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol-Myers Squibb Stock Performance

NYSE:BMY traded up $0.07 during mid-day trading on Monday, reaching $42.71. The stock had a trading volume of 10,113,928 shares, compared to its average volume of 15,680,470. The company has a debt-to-equity ratio of 2.99, a quick ratio of 0.99 and a current ratio of 1.11. The firm has a market capitalization of $86.58 billion, a price-to-earnings ratio of -13.81, a PEG ratio of 15.55 and a beta of 0.44. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $65.38. The business has a 50 day simple moving average of $41.68 and a 200 day simple moving average of $46.99.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, beating analysts’ consensus estimates of ($4.53) by $0.13. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The firm had revenue of $11.87 billion during the quarter, compared to the consensus estimate of $11.45 billion. During the same quarter last year, the firm earned $2.05 earnings per share. The firm’s revenue was up 4.7% compared to the same quarter last year. On average, analysts expect that Bristol-Myers Squibb will post 0.55 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, August 1st. Stockholders of record on Friday, July 5th will be given a dividend of $0.60 per share. The ex-dividend date is Friday, July 5th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 5.62%. Bristol-Myers Squibb’s payout ratio is -77.42%.

Wall Street Analyst Weigh In

Several equities analysts recently commented on BMY shares. BMO Capital Markets dropped their target price on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a report on Friday, April 26th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $45.00 price objective on shares of Bristol-Myers Squibb in a report on Monday. Barclays dropped their price objective on Bristol-Myers Squibb from $43.00 to $41.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 10th. StockNews.com lowered Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Thursday, June 27th. Finally, Wells Fargo & Company raised their price objective on Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a report on Thursday, April 18th. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $58.40.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.